The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis.

Objective: To estimate the impact of persistence on cost-effectiveness of subcutaneous tumor necrosis factor-α inhibitors (SC-TNFis) from healthcare and societal perspectives in a United Kingdom ankylosing spondylitis (AS) population using a recently published Markov cohort model.

Methods: A recently published cost-effectiveness model developed for a National Institute for health and Care Excellence appraisal was extended to fit the current study; in brief, it is a Markov cohort model where treatment responders continue from the trial period with maintenance SC-TNFi treatment, while non-responders transition to conventional care. Costs and effects were modeled for a hypothetical SC-TNFi with average efficacy and price.

Epidemiology and economic burden of osteoporosis in Switzerland.

Unlabelled: This report describes the epidemiology, economic burden and treatment of osteoporosis in Switzerland.

Introduction: Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting in increased risks of fragility fractures which represent the main clinical consequence of the disease. Fragility fractures are associated with substantial pain and suffering, disability and even death for the affected patients and substantial costs to society.

Osteoporosis in the European Union: a compendium of country-specific reports.

Unlabelled: This report describes epidemiology, burden, and treatment of osteoporosis in each of the 27 countries of the European Union (EU27).

Introduction: In 2010, 22 million women and 5.5 million men were estimated to have osteoporosis in the EU; and 3.

Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA).

Unlabelled: This report describes the epidemiology, burden, and treatment of osteoporosis in the 27 countries of the European Union (EU27).

Introduction: Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting in increased risk of fragility fractures which represent the main clinical consequence of the disease. Fragility fractures are associated with substantial pain and suffering, disability and even death for affected patients and substantial costs to society.

The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)--quality of life during the first 4 months after fracture.

Unlabelled: The quality of life during the first 4 months after fracture was estimated in 2,808 fractured patients from 11 countries. Analysis showed that there were significant differences in the quality of life (QoL) loss between countries. Other factors such as QoL prior fracture and hospitalisation also had a significant impact on the QoL loss.